> Back to EJC

 

Previous editions of EJC News Focus

  • November 2011
    Gordon Mills assesses the challenges we face in developing personalised medicine.
  • October 2011
    Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
  • September 2011
    Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
  • August 2011
    Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
  • July 2011
    EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
  • June 2011
    Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
  • April/May 2011
    Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
  • March 2011
    EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
  • February 2011
    Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
  • January 2011
    Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.

EJC News Focus – March 2011

Loading EJC News Focus video

 

This month's EJC News Focus video comes from the International Congress on Anticancer Treatment in Paris. Helen Saul discussed the disappointing findings of recent trials of bevacizumab in colon cancer* with EJC’s editor for gastrointestinal cancers, Professor Eric van Cutsem (Leuven, Belgium).

 

*Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. Allegra CJ, et al. J Clin Oncol 2011. 29: 11-16

Lessons from the adjuvant bevacizumab trial on colon cancer: What next? Van Cutsem E, et al. J Clin Oncol 2011 29: 1-10

Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. Miles D, et al. J Clin Oncol 2011. 29: 83-88

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. De Gramont A, et al. J Clin Oncol 2011. 29 (suppl 4) Abstract 362